What is CS Bio?
CS Bio, founded in 1993 and headquartered in Silicon Valley, California, is a leading provider of automated peptide and DNA synthesizers. The company caters to the global pharmaceutical sector, with its advanced synthesis systems deployed in over 30 countries. Its clientele spans universities, research institutions, and biotechnology firms, highlighting the broad applicability and reliability of CSBio's technology. Offering a spectrum of synthesizers from research-scale to commercial production, CSBio also specializes in custom-built solutions tailored to unique client requirements. With over three decades of industry experience, CSBio is recognized for its innovative and dependable synthesis instrumentation.
How much funding has CS Bio raised?
CS Bio has raised a total of $2.5M across 2 funding rounds:
Debt
$1M
Debt
$1.5M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.5M led by PPP
What's next for CS Bio?
The recent major strategic investment in CS Bio signals a pivotal moment for the company, likely enabling accelerated product development, expansion into new markets, or enhancement of its manufacturing capabilities. This capital infusion is expected to fortify CS Bio's competitive edge in the peptide and DNA synthesis market, supporting its mission to provide cutting-edge instrumentation to the pharmaceutical and research communities worldwide. The company's focus on custom solutions and its extensive experience position it well for continued innovation and growth.
See full CS Bio company page
